Neuland Laboratories Limited (NEULANDLAB)
₹19,675.00 -1.40% last close, 16 Oct
Latest quarterly results (Q4 FY26)
In its latest reported quarter, Q4 FY26, Neuland Laboratories' revenue was ₹776 Cr (+136.3% year on year, +76.5% on the previous quarter), and net profit ₹213 Cr (+668.0% year on year); the operating margin was 39.6%.
| Q4 FY26 (₹ Cr) | Value | YoY vs Q4 FY25 | QoQ |
|---|---|---|---|
| Revenue | ₹776 | +136.3% | +76.5% |
| Operating profit | ₹307 | +504.9% | +299.1% |
| Net profit | ₹213 | +668.0% | +427.0% |
| EPS (₹) | 165.64 | +666.1% | +425.8% |
| Operating margin | 39.6% | — | — |
NEULANDLAB delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 38.22% of the NEULANDLAB shares traded on NSE were taken to delivery, against the stock's own 20-session average of 47.9%. That is lower than usual for this stock.
Delivery in the last 5 sessions: 37.6% · 44.7% · 47.7% · 59.9% · 38.2%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Neuland Laboratories has received an Establishment Inspection Report (EIR) from the US FDA for its Unit 3 manufacturing facility located at Gaddapotharam village, Sangareddy District. The inspection, conducted between August 10, 2026, and August 14, 2026, has been officially closed by the regulator. This clears regulatory uncertainty for Unit 3, a vital facility considering exports account for 82% of company sales, with regulated US/EU markets comprising 89% of exports.
- US FDA issued an Establishment Inspection Report (EIR) for Unit 3 facility.
- The regulatory inspection was conducted from August 10, 2026 to August 14, 2026.
- US FDA formally concluded that the inspection is closed.
- Secures compliance for a facility serving regulated export markets (exports represent 82% of company sales).
Neuland Laboratories Limited has informed the exchanges regarding its participation in an investor conference. The company's management is scheduled to attend the Goldman Sachs Global Healthcare CDMO Day from September 23 to September 25, 2026, in Singapore. The interaction will involve group and one-on-one meetings with institutional investors. This is a routine investor relations update and does not disclose any price-sensitive financial or operational decisions.
- Event scheduled from September 23 to 25, 2026
- Participation in Goldman Sachs Global Healthcare CDMO Day in Singapore
- Meeting format includes both group meets and one-on-one meets
- Filing made under Regulation 30 of SEBI LODR Regulations, 2015
Neuland Laboratories has commenced operations at the first of four scheduled commercial peptide manufacturing modules following a $30 million investment. Module 1 adds 7,000 L of total reactor capacity (750 L SPPS and 6,250 L LPPS) supported by 212 peptide experts. The company is advancing Module 2, which is planned to add up to 18,000 L of reactor capacity tailored to anchor customer requirements. This operational scale-up supports Neuland's growing CMS pipeline in high-margin complex peptides across obesity, metabolic disease, and oncology.
- Module 1 is now operational after an investment of $30 million (~₹250 Cr)
- Module 1 adds 7,000 L total reactor capacity (750 L SPPS, 6,250 L LPPS) and two lyophilisers (100 L and 200 L)
- Module 2 is planned to add up to 18,000 L in total reactor capacity with foundational infrastructure already in place
- Facility backed by a team of nearly 212 peptide experts
Neuland Laboratories Limited has informed the exchanges that its management will participate in two upcoming group investor meetings in Hyderabad. The meetings include the Emkay Global Investors Meeting on September 15, 2026, and the ICICI Securities - Hyderabad Healthcare Day on September 17, 2026. This announcement is purely procedural and does not include any operational or financial updates.
- Management to attend Emkay Global Investors Meeting on September 15, 2026
- Management to participate in ICICI Securities - Hyderabad Healthcare Day on September 17, 2026
- Both interactions scheduled as group meets in Hyderabad
Neuland Laboratories' Board of Directors has approved a capital expenditure of ₹126 crore to purchase approximately 134 acres of land at Auro Industrial City, Kakinada, Andhra Pradesh. The company also secured a right of first refusal for an additional contiguous 66 acres, creating a potential aggregate land bank of 200 acres for future expansion. The transaction will be funded entirely through internal accruals, representing approximately 6.2% of TTM revenue (₹2,023 crore) and 6.8% of net worth (₹1,866 crore). Concrete capacity figures and project execution schedules will be determined in subsequent phases.
- Approved capital expenditure of ₹126 crores for land purchase and related expenditure
- Acquiring approximately 134 acres of industrial land at Auro Industrial City, Kakinada, Andhra Pradesh
- Right of first refusal secured for an additional ~66 contiguous acres, allowing expansion up to ~200 acres
- Entire investment funded via internal accruals without requiring external debt
Neuland Laboratories announced that CRISIL Ratings has reaffirmed its long-term credit rating at 'CRISIL A+' while revising the outlook upward to 'Positive'. The short-term credit rating has been reaffirmed at 'CRISIL A1'. The outlook revision reflects strengthening business performance and strong financial risk profile, supported by low debt of ₹301 Cr against a net worth of ₹1,866 Cr (D/E of 0.16x).
- Long-term credit rating reaffirmed at 'CRISIL A+' by CRISIL Ratings
- Long-term rating outlook revised to 'Positive'
- Short-term credit rating reaffirmed at 'CRISIL A1'
- Supports company's low-leverage balance sheet with total debt at ₹301 Cr vs net worth of ₹1,866 Cr
Neuland Laboratories completed a 5-day US FDA inspection at its Unit 3 manufacturing facility in Gaddapotharam, Sangareddy District, held from August 10 to August 14, 2026. The inspection concluded with the issuance of Form 483 with 1 observation. The observation relates to procedural improvements in water and environmental monitoring to cover new organisms beyond USP listings. The company confirmed it will submit its response to the US FDA within stipulated timelines.
- US FDA inspected Unit 3 manufacturing facility from August 10 to August 14, 2026 (5 days)
- Issued Form 483 with 1 observation regarding water and environmental monitoring procedures
- Observation focuses on procedural inclusion of organisms beyond United States Pharmacopeia (USP) guidelines
- Company committed to submitting its formal response within the regulator's stipulated timelines
Neuland Laboratories reported a strong Q1 FY27 with revenue growing 16.3% YoY to ₹650.1 cr, primarily driven by commercial CMS projects. Profitability saw a significant jump with PAT reaching ₹147.4 cr compared to ₹13.7 cr in the same quarter last year, supported by a high EBITDA margin of 35.5%. The company approved a new ₹203 cr capex for strategic growth, including capacity expansion at Unit 1. Working capital efficiency improved remarkably, with cycle days reducing from 137 to 84 days.
- Revenue increased 16.3% YoY to ₹650.1 cr in Q1 FY27, driven by commercial CMS molecules.
- EBITDA margin expanded to 35.5% due to favorable product mix and operating leverage.
- Approved ₹203 cr in new capital investments, with ₹196 cr dedicated to Unit 1 capacity expansion.
- Working capital cycle improved to 84 days from 137 days at the end of FY26.
- Total approved capex over the last 13 quarters reached ₹1,460 cr, with ₹870 cr already deployed.
Neuland Laboratories has announced its participation in the Emkay Confluence 2026 investor conference scheduled for August 12, 2026, in Mumbai. The management will engage in both group and one-on-one meetings with institutional investors and analysts. This is a routine investor relations activity for the company, which currently has a market capitalization of ₹28,698 Cr. No material non-public information is expected to be shared during these sessions.
- Meeting scheduled for August 12, 2026, in Mumbai
- Participation in the Emkay Confluence 2026 event
- Format includes both Group and One-on-One interactions
- Company maintains a high P/E ratio of 78.8 as of the announcement date
Neuland Laboratories has released the audio recording of its earnings call for the quarter ended June 30, 2026, held on August 5, 2026. This follows a strong FY26 performance where the company achieved a TTM revenue of ₹2,023 Cr and a PAT of ₹364 Cr. Investors should listen for updates on the CMS (Contract Manufacturing) pipeline, which included 98 projects as of Q2 FY26, and the progress of the ₹170.7 Cr H1 FY26 capex. The company's high P/E of 70.4 reflects market expectations for its transition into complex peptides and specialty molecules.
- Earnings call for the quarter ended June 30, 2026, conducted on August 5, 2026
- Company reported TTM revenue of ₹2,023 Cr with an operating margin of 28.4%
- CMS pipeline included 98 total projects and 18 commercial molecules as of Q2 FY26
- Recent Capex of ₹170.7 Cr in H1 FY26 focused on expanding capacity for peptides
Neuland Laboratories is expanding its Unit 1 capacity by 18 KL (a ~4.8% increase) with an investment of 39.8 crores to address high utilization levels of 91%. More significantly, the company has entered a long-term strategic partnership with Gland Pharma to establish a dedicated 1,400 kg annual capacity sterile API suite for complex microparticle depot products. Neuland will provide a 40 crore corporate guarantee to support this collaboration, which leverages Gland's sterile manufacturing and Neuland's complex chemistry expertise.
- Unit 1 capacity expansion of 18 KL to be added to the existing 376.5 KL base within 6-7 months
- Investment of 39.8 crores for Unit 1 expansion to be funded entirely through internal accruals
- Strategic partnership with Gland Pharma for a dedicated 1,400 kg annual capacity sterile API suite
- Issuance of a 40 crore corporate guarantee in favor of Gland Pharma for a Loan License Agreement
- Unit 1 currently operating at a high utilization rate of 91%, necessitating the expansion
Neuland Laboratories has entered a long-term strategic CDMO partnership with Gland Pharma to manufacture sterile APIs for complex microparticle depot products. As part of this agreement, Neuland will provide a Rs 40 crore corporate guarantee to Gland Pharma, which is establishing a dedicated 1,400 kg annual capacity suite at its Visakhapatnam facility. Additionally, Neuland is investing Rs 39.8 crore to expand its own Unit 1 capacity by 18 KL to meet growing demand, as current utilization has reached 91%. The expansion is funded through internal accruals and is expected to be completed within 6-7 months.
- Rs 40 crore corporate guarantee issued to Gland Pharma for dedicated manufacturing capacity
- 1,400 kg annual capacity suite to be established by Gland Pharma for Neuland's sterile APIs
- Rs 39.8 crore investment for 18 KL capacity addition at Neuland's Unit 1 facility
- 6-7 months timeline for the completion of the Unit 1 expansion
- 91% current capacity utilization at Unit 1, necessitating the immediate expansion
Neuland Laboratories reported a robust Q1 FY27 with total income growing 116.3% YoY to ₹650.1 Cr. The growth was primarily driven by the CMS (Custom Manufacturing Solutions) segment, which saw revenue surge to ₹418 Cr from ₹120 Cr in the same quarter last year. EBITDA margins expanded significantly by 2,150 bps to 35.5%, resulting in a PAT of ₹147.4 Cr compared to ₹13.7 Cr YoY. The company also improved its working capital cycle to 84 days and maintained a strong net cash position of ₹308.5 Cr.
- Total Income for Q1 FY27 reached ₹650.1 Cr, a 116.3% increase over Q1 FY26.
- CMS segment revenue grew to ₹418 Cr, now contributing approximately 64% of total revenue.
- EBITDA margins expanded to 35.5% from 14.0% YoY, driven by high-margin commercial molecules.
- Active CMS projects stood at 99, with 19 molecules in the commercial stage and 13 in Phase-3.
- Working capital days reduced to 84 days in Q1 FY27 from 137 days in Q4 FY26.
Neuland Laboratories reported a massive 975% YoY increase in Profit After Tax (PAT) to ₹147.4 cr for Q1 FY27, compared to ₹13.7 cr in Q1 FY26. Total income grew 116.3% YoY to ₹650.1 cr, driven by strong performance in the CMS and GDS segments, although it declined 17.6% sequentially from a high Q4 FY26 base. EBITDA margins expanded significantly by 2150 bps YoY to 35.5%, reflecting a shift toward higher-margin complex molecules. The company indicated that investment intensity will increase to capitalize on pipeline opportunities in the peptide and specialty space.
- Profit After Tax (PAT) surged 975% YoY to ₹147.4 cr from ₹13.7 cr in the year-ago period.
- EBITDA margins expanded by 2150 bps YoY to 35.5%, up from 14.0% in Q1 FY26.
- Total income for the quarter reached ₹650.1 cr, representing approximately 32% of the TTM revenue.
- Earnings Per Share (EPS) increased to ₹114.9 from ₹10.7 in the previous year's corresponding quarter.
- Management confirmed that all significant Capex projects are proceeding as planned with increased investment intensity expected.
Neuland Laboratories has entered a long-term strategic CDMO partnership with Gland Pharma to establish a dedicated 1,400 kg annual capacity sterile API suite at Gland's Visakhapatnam facility. To support this, Neuland is providing a Rs 40 Cr corporate guarantee to Gland Pharma. Simultaneously, Neuland is expanding its own Unit 1 capacity by 18 KL (reaching 394.5 KL) with a Rs 39.8 Cr investment to address high utilization levels of 91%. These initiatives signal a strategic push into high-margin complex sterile injectables and peptides.
- Strategic partnership with Gland Pharma to create a 1,400 kg annual capacity sterile API manufacturing suite
- Rs 39.8 Cr investment for an 18 KL capacity addition at Unit 1 to meet growing demand
- Current Unit 1 capacity utilization stands at 91%, necessitating the 6-7 month expansion timeline
- Execution of a Rs 40 Cr corporate guarantee in favor of Gland Pharma for manufacturing obligations
- Expansion and partnership focus on high-value complex chemistry and sterile injectable therapies
Financial Performance
Revenue Growth by Segment
The CMS (CDMO) segment now contributes over 50% of total revenues. Overall operating income for FY25 was INR 1,476.84 Cr, representing a 5.2% decline from INR 1,558.58 Cr in FY24. However, Q2 FY26 achieved 'record high' revenues driven by commercial CMS projects.
Geographic Revenue Split
Exports account for 82% of total revenue. Within exports, the US and Europe are the primary markets, contributing over 89% of total export earnings (approximately 73% of total company revenue).
Profitability Margins
The reported Profit After Tax (PAT) margin for FY25 was 17.61%, with a total PAT of INR 260.11 Cr. This was a decrease from the 19.25% margin (INR 300.08 Cr) recorded in FY24.
EBITDA Margin
The EBITDA margin reached 30% in Q2 FY26, matching the high of 30% seen in FY24. This margin is driven by operating leverage from high-volume commercial CMS projects and a favorable product mix of specialty molecules.
Capital Expenditure
The company invested INR 170.7 Cr in CAPEX during H1 FY26, with INR 91 Cr spent in Q2 FY26 alone. These investments are directed toward strengthening capabilities in complex specialty molecules and peptides.
Credit Rating & Borrowing
CRISIL has assigned a 'Stable' rating. The company has an annual term debt obligation of approximately INR 40 Cr, which is well-covered by expected annual cash accruals exceeding INR 300 Cr.
Operational Drivers
Raw Materials
The company utilizes complex API intermediates and chemical reagents. Specific chemical names and their individual cost percentages are not disclosed in available documents.
Import Sources
Raw materials are sourced from both domestic (India) and global markets. The company actively monitors global market trends to manage volatility in input prices.
Capacity Expansion
Neuland operates 3 US FDA-approved manufacturing facilities in Hyderabad, Telangana. While specific MTPA capacity is not disclosed, the INR 170.7 Cr H1 FY26 CAPEX is focused on expanding capacity for peptides and complex molecules.
Raw Material Costs
Raw material costs are subject to pricing pressure from the global bulk drugs industry. The company employs a multi-sourcing strategy to reduce dependency on single suppliers and mitigate price fluctuations.
Manufacturing Efficiency
The company focuses on process research and development to improve yields. Specific capacity utilization percentages are not disclosed.
Strategic Growth
Growth Strategy
Growth is targeted through the transition of molecules from clinical phases to commercial production within the CMS segment (98 total projects in Q2 FY26). The company is specifically investing in peptide capabilities and complex specialty generic APIs to differentiate from standard generic competitors.
Products & Services
The company sells complex Active Pharmaceutical Ingredients (APIs), intermediates, and provides Contract Development and Manufacturing Organization (CDMO/CMS) services for innovators.
Brand Portfolio
Neuland Laboratories Limited.
New Products/Services
New product focus is centered on the 'peptide space' and complex specialty molecules. The CMS pipeline added 18 commercial molecules as of Q2 FY26.
Market Expansion
Expansion is focused on regulated markets in the US and Europe, supported by market development subsidiaries in the USA (Neuland Laboratories Inc.) and Japan (Neuland Laboratories K.K.).
Strategic Alliances
The company operates through two wholly-owned subsidiaries in the USA and Japan. No third-party joint ventures or associate companies are reported.
External Factors
Industry Trends
The industry is shifting from simple generics to innovation-driven CDMO solutions. Neuland is positioning itself to benefit from this 'significant transformation' by focusing on complex chemistry and commercializing innovator molecules.
Competitive Landscape
The landscape is highly competitive, featuring global API manufacturers and large-scale players from China who exert pricing pressure on bulk drugs.
Competitive Moat
The moat is based on a 40-year track record, 3 US FDA-approved facilities, and deep expertise in complex chemistry (e.g., peptides). This creates high switching costs for innovator clients who require validated GMP manufacturing partners.
Macro Economic Sensitivity
The business is sensitive to global inflation and healthcare spending trends. Rising consumerization of healthcare and government pushes for innovation-driven solutions in India are positive macro drivers.
Consumer Behavior
There is an increasing consumer focus on holistic health and a growing demand for specialty medications, which drives the need for complex APIs.
Geopolitical Risks
Geopolitical events are cited as a potential cause for supply chain disruptions and market volatility in input prices.
Regulatory & Governance
Industry Regulations
Operations are governed by strict US FDA and EMA standards. The company has 988 worldwide filings, including 499 European DMFs and 72 active US DMFs, requiring constant compliance to maintain market access.
Environmental Compliance
The company achieved a global ESG score of 70 out of 100 from S&P Global. It has developed a carbon accounting tool in partnership with CII-IGBC to disclose emissions data.
Legal Contingencies
There are no significant or material orders passed by regulators or courts that impact the company's going concern status or future operations as of the latest report.
Risk Analysis
Key Uncertainties
Key risks include regulatory non-compliance (impacting 82% of revenue), raw material price volatility, and the 'lumpy' or uneven nature of the CMS business which depends on clinical trial success and innovator timelines.
Geographic Concentration Risk
High concentration in the US and Europe, which account for over 73% of total revenue via exports.
Third Party Dependencies
The company is working to reduce dependency on single-source suppliers for raw materials to mitigate supply chain disruptions.
Technology Obsolescence Risk
The company faces risks from rapid technological changes in drug development. It mitigates this through continuous R&D and digital transformation of internal processes.
Credit & Counterparty Risk
Debtor days were 78 in FY25. However, Q2 FY26 saw a deterioration in working capital due to higher receivables (155 days of sales) resulting from uneven order flows.
